Moclobemide, a critical pharmaceutical intermediate with CAS number 71320-77-9, is more than just a precursor; it's a precisely engineered molecule that forms the backbone of important therapeutic agents. NINGBO INNO PHARMCHEM CO.,LTD. specializes in the synthesis of this compound, ensuring it meets the exacting standards required for pharmaceutical applications.

The chemical structure of Moclobemide, a benzamide derivative, imbues it with its unique pharmacological properties as a selective, reversible inhibitor of monoamine oxidase A (RIMA). The synthesis process involves multiple steps, each carefully controlled to maximize yield and purity. Key to its efficacy is the precise arrangement of its chemical groups, which allows it to interact with MAO-A enzymes without causing irreversible damage. This selectivity is a major advantage over older MAOIs, contributing to a better safety profile and fewer drug interactions.

NINGBO INNO PHARMCHEM CO.,LTD. employs advanced chemical synthesis techniques to produce Moclobemide powder at 99% purity. Our manufacturing processes are validated and adhere to GMP guidelines, ensuring consistency and quality across all batches. The focus on producing a high-purity pharmaceutical intermediate like Moclobemide means that drug manufacturers can rely on the chemical integrity of the starting material for their API synthesis. This is crucial when considering the antidepressant raw material price; the cost reflects not just the material itself but the meticulous process behind its creation.

Understanding the chemical characteristics of this reversible MAOI intermediate is essential for formulators. The physical form—a white powder—and its solubility properties are important considerations for downstream processing. As a supplier of this vital CAS 71320-77-9 chemical, NINGBO INNO PHARMCHEM CO.,LTD. provides comprehensive technical data to support your formulation and synthesis efforts. The reliability of Moclobemide as a building block is a testament to the advancements in chemical synthesis within the pharmaceutical industry.